Hofseth BioCare ASA
HOFBF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.48 | 0.27 | 0.17 | -0.16 |
| FCF Yield | -0.47% | -5.43% | -3.64% | -0.08% |
| EV / EBITDA | -48.64 | -89.05 | -30.65 | -23.13 |
| Quality | ||||
| ROIC | -17.58% | -5.38% | -11.24% | -15.79% |
| Gross Margin | 35.54% | 47.77% | 38.44% | 29.86% |
| Cash Conversion Ratio | -0.05 | 1.25 | 0.41 | -0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.23% | 17.52% | 26.81% | 30.12% |
| Free Cash Flow Growth | 90.62% | -121.49% | -4,162.06% | 98.59% |
| Safety | ||||
| Net Debt / EBITDA | 5.08 | -21.94 | -8.44 | -5.48 |
| Interest Coverage | -5.16 | -2.49 | -7.17 | -7.93 |
| Efficiency | ||||
| Inventory Turnover | 0.48 | 0.53 | 0.68 | 0.81 |
| Cash Conversion Cycle | -96.63 | -36.23 | -77.16 | -48.36 |